Resultado de búsqueda
Revolution Medicines is building a deep pipeline in support of its focus on the development and delivery of novel targeted therapies to patients with RAS-addicted cancers.
Background. Preclinical data for RMC-6236. Clinical trial design and initial toxicity and efficacy data for RMC-6236-001 trial. Future directions for RAS inhibition in pancreatic cancer. KRAS. mutant alleles by cancer type. KRAS mutations are most common in the three leading causes of cancer death in US:
17 de ago. de 2023 · The paper describes the Revolution Medicines tri-complex inhibitor approach to developing novel small molecules with high affinity and selectivity for the active state of mutant RAS, or RAS(ON), proteins that are common causes of human cancer and were previously considered undruggable.
At Revolution Medicines our mission is to revolutionize treatment for patients with RAS-addicted cancers through targeted medicines.
4 de dic. de 2023 · Revolution Medicines’ RAS(ON) inhibitors completely differ from the currently approved G12C RAS(OFF) inhibitors mechanistically, which may bring new hope to KRAS precision therapy.
19 de sept. de 2023 · KRAS G12D is the most common driver of RAS-addicted human cancers, accounting for nearly 55,000 newly diagnosed patients in the U.S. annually, predominantly among patients with pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer.
Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), PDAC and colorectal cancer (CRC). RAS G12 mutations, such as G12D, G12V and G12C, predominate in human cancers.
